The rationale for the study was anecdotal reports of the effects of breast milk used by mothers to treat blocked tear ducts, ...

KPI-012, which is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), leverages KALA's proprietary mesenchymal stem cell secretome (MSC-S ...

One eye with membranous keratoconjunctivitis with symblepharon showed resolution of corneal epithelial defect on the seventh day. The ocular surface healed completely with no symblepharon at the ...

Bazemore expressed his commitment to advancing KALA's lead product candidate, KPI-012, which is currently in Phase 2b trials for treating persistent corneal epithelial defect (PCED). Bazemore has ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

ARLINGTON, Mass. - KALA BIO, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on developing treatments for rare and severe eye diseases, announced a change in its executive leadership on Monday ...

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company ...